LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Joint Statement: The Data Act is a leap into the unknown

01/02/2023
POSITION PAPER

1 February 2023

Data sharing will be fundamental to the success of the European economy in the coming years, with data contributing at least €1 trillion by 2030. But the Data Act as it stands is a huge leap into the unknown, affecting the fundamentals of European companies’ data-driven business models, with only the promise of a better data future.

As the policymaking process accelerates on this pivotal proposal, industry warns against possible unintended economic consequences across data value chains.

At a time of great economic upheaval, record-high energy prices and the negative impact of pandemic and war on global supply chains, what industry needs to succeed is stability, not more uncertainty. Before opening Pandora’s box, the Data Act’s rules need to be tried and tested in real-world market conditions to make sure that they work for European businesses.

The opposite result will be achieved if the Data Act rushes to impose widespread data sharing onto unsuspecting businesses already overwhelmed by an unprecedented amount of new regulation.

The European Parliament and Council should take sufficient time to preserve European innovation and competitiveness. Concretely, they must ensure that the proposal:

  • Protects trade secrets, safety, security and privacy by including effective safeguards to prevent data misuse and unfair competition;
  • Gives certainty to companies as to if and what they must share, starting by setting clear definitions, e.g. ‘data’ and ‘data holder’;
  • Enables companies to find mutually beneficial data-driven relationships by recognising the central role of flexible contractual terms, including on compensation;
  • Differentiates between the business-to-business (B2B) and the business-to-consumer (B2C) contexts and provides different rules and safeguards accordingly;
  • Sets strict conditions to business-to-government (B2G) data requests and limits the scope to public emergencies, to avoid endless litigation and uncertainty for Member States;
  • Promotes cloud adoption through an applicable and adaptable switching framework that reflects technical reality and market needs, and provides legal clarity;
  • Does not create new obstacles to international data flows, which are critical to European companies’ operation and growth in foreign markets;
  • Allows for a longer transition period, of at least 36 months, to give companies time to prepare, and does not apply retroactively to ensure predictability of current investments.

We trust that EU policymakers will take the time to build a framework that supports Europe’s data economy.

Joint statement: The Data Act is a leap into the unknown


Download
2020_12_G_PP_Comitology Joint StatementDownload

Share
Communications Team
Communications Team

Related posts

14/11/2025

Vial joins EuropaBio: Reimagining Drug Development with Hyper-Scalable Biotech


Read more
12/11/2025

EuropaBio response to the EU Biotech Act public consultation


Read more
05/11/2025

EuropaBio recommendations for the Circular Economy Act


Read more

Important links

  • Vial joins EuropaBio: Reimagining Drug Development with Hyper-Scalable Biotech
  • EuropaBio response to the EU Biotech Act public consultation

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.